OTHER FINANCIAL ASSETS Sample Clauses

OTHER FINANCIAL ASSETS. The other financial assets in the amount of EUR 595 thousand mature within one year from the reporting date and consist of other costs charged to customers (2008: EUR 85 thousand). In addition, the item included the positive fair values of the forward exchange contracts in the previous year (EUR 2,601 thousand). Further information on the forward exchange contracts will be found in Note 4.3.2. Disclosures on derivative financial instruments and hedging.
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
OTHER FINANCIAL ASSETS. All other financial assets of the AAMC, including cash reserves, investment accounts, and gift funds or liquid assets received and recorded as gifts to the AAMC by or before June 30, 2007, are subject to exclusive rights of ownership and control by the AAMC. As of July 1, 2007, all donor gifts made to support AAMC alumnae relations, the AAMC alumnae relations budget, or AAMC programs or operations will transfer to the College consistent with the provisions of this MOA.
Sample 1Sample 2
OTHER FINANCIAL ASSETS. Consisted of : Baht Consolidated financial statements Separate financial statements As at June 30, 2022 As at December 31, 2021 As at June 30, 2022 As at December 31, 2021 Other current financial assets Financial assets at fair value through income or loss Investments in listed securities (Note 10.1) 967,470,000 757,619,998 967,470,000 757,619,998 Total other current financial assets 967,470,000 757,619,998 967,470,000 757,619,998 Other non - current financial assets Financial assets at fair value through other comprehensive income Investments in listed securities (Note 10.1) 13,001,056,350 11,093,014,712 8,627,046,915 7,648,821,330 Investments in non-listed equity instruments (Note 10.2) 1,205,459,214 1,197,959,214 867,842,454 867,842,454 Total other non - current financial assets 14,206,515,564 12,290,973,926 9,494,889,369 8,516,663,784 Total other financial assets 15,173,985,564 13,048,593,924 10,462,359,369 9,274,283,782 10.1 Investment in listed securities consisted of : Baht Consolidated financial statements Separate financial statements As at June 30, 2022 As at December 31, 2021 As at June 30, 2022 As at December 31, 2021 Financial assets at fair value through income or loss Investment in listed securities 1,098,676,315 740,600,206 1,098,676,315 740,600,206 Unrealized gain (loss) on valuation of securities (131,206,315) 17,019,792 (131,206,315) 17,019,792 Total 967,470,000 757,619,998 967,470,000 757,619,998 Financial assets at fair value through other comprehensive income Investment in listed securities 4,756,783,075 4,612,062,736 4,029,972,296 3,890,888,671 Unrealized gain on valuation of securities 8,244,273,275 6,480,951,976 4,597,074,619 3,757,932,659 Total 13,001,056,350 11,093,014,712 8,627,046,915 7,648,821,330 The movement for the six-month period ended June 30, 2022 was as follows: Baht Consolidated financial statements Separate financial statements Fair value through income or loss Fair value through other comprehensive income Fair value through income or loss Fair value through other comprehensive income Balance as at January 1, 2022 757,619,998 11,093,014,712 757,619,998 7,648,821,330 Increase 420,671,584 148,019,677 420,671,584 139,083,624 Decrease (62,595,474) (3,299,337) (62,595,474) - Change in valuation (148,226,108) 1,763,321,298 (148,226,108) 839,141,961 Balance as at June 30, 2022 967,470,000 13,001,056,350 967,470,000 8,627,046,915 For the six-month period ended June 30, 2022 and 2021, the Company and its subsidiaries received...
Sample 1
OTHER FINANCIAL ASSETS. Consisted of: Baht Consolidated financial statements Separate financial statements As at September 30, 2021 As at December 31, 2020 (Restate) As at September 30, 2021 As at December 31, 2020 (Restate) Other current financial assets Financial assets at fair value through income or loss Investments in listed securities (Note 10.1) 716,810,000 156,910,000 716,810,000 156,910,000 Total other current financial assets 716,810,000 156,910,000 716,810,000 156,910,000 Other non - current financial assets Financial assets at fair value through other comprehensive income Investments in listed securities (Note 10.1) 9,040,111,138 6,750,758,766 6,443,885,664 4,316,151,372 Investments in non-listed equity instrument (Note 10.2) 1,061,623,651 982,498,651 741,506,891 662,381,891 Financial assets at amortized cost Investments in debt securities held to maturity (Note 10.3) - 10,000,000 - 10,000,000 Total other non - current financial assets 10,101,734,789 7,743,257,417 7,185,392,555 4,988,533,263 Total other financial assets 10,818,544,789 7,900,167,417 7,902,202,555 5,145,443,263
Sample 1
OTHER FINANCIAL ASSETS. This caption includes investment income receivable, and certain other receivables. The carrying amount of these assets approximates their fair value. Other Financial Liaibilities. This caption includes payables on taxes due to the federal and state governments, accruals for certain employee related compensation and certain other payables. The carrying amount of these liabilities approximates their fair value.
Sample 1
OTHER FINANCIAL ASSETS. Consisted of: Baht Consolidated financial statements Separate financial statements As at March 31, 2021 As at December 31, 2020 (Restate) As at March 31, 2021 As at December 31, 2020 (Restate) Other current financial assets Financial assets at fair value through income or loss Investments in listed securities (Note 10.1) 400,364,021 156,910,000 400,364,021 156,910,000 Total other current financial assets 400,364,021 156,910,000 400,364,021 156,910,000 Other non - current financial assets Financial assets at fair value through other comprehensive income Investments in listed securities (Note 10.1) 7,468,772,379 6,750,758,766 4,959,631,566 4,316,151,372 Investments in non-listed equity instrument (Note 10.2) 982,498,651 982,498,651 662,381,891 662,381,891 Financial assets at amortized cost Investments in debt securities held to maturity (Note 10.3) 10,000,000 10,000,000 10,000,000 10,000,000 Total other non - current financial assets 8,461,271,030 7,743,257,417 5,632,013,457 4,988,533,263 Total other financial assets 8,861,635,051 7,900,167,417 6,032,377,478 5,145,443,263 10.1 Investment in listed securities‌ The movement for the three-month periods ended March 31, 2021 was as follows: Baht Consolidated financial statements Separate financial statements Fair value through income or loss Fair value through other comprehensive income Fair value through income or loss Fair value through other comprehensive income Balance as at January 1, 2021 156,910,000 6,750,758,766 156,910,000 4,316,151,372 Increase during the period 208,036,833 186,125,743 208,036,833 186,079,182 Decrease during the period (37,538,066) - (37,538,066) - Loss on change in value 72,955,254 531,887,870 72,955,254 457,401,012 Balance as at March 31, 2021 400,364,021 7,468,772,379 400,364,021 4,959,631,566 For the three-month period ended March 31, 2021 and 2020, the Company and its subsidiaries received dividend from above investment as follow Baht Consolidated financial statements Separate financial statements 2021 2020 2021 2020 Dividend 55,546,375 74,837,473 24,228,785 11,163,362 Sikarin Public Co., Ltd. As at March 31, 2021, the Company has pledged this share of Sikarin Co., Ltd. in the amount of shares 244,000,000, with a financial institution to secure the credit facilities as discussed in Note 20 to the interim financial statements. Ramkhamhaeng Hospital Public Co., Ltd. As at March 31, 2021, the Company has pledged this share of Ramkhamhaeng Hospital Co., Ltd. in the amount of shares 10,...
Sample 1

Related to OTHER FINANCIAL ASSETS

  • Financial Assets It will promptly credit each item of property (whether cash, investment property, security, instrument or other financial asset) delivered to the Financial Institution under the Indenture to the Collateral Account and treat each item of property as a “financial asset” (within the meaning of Section 8-102(a)(9) of the UCC); and

  • “Financial Assets” Election The Financial Institution hereby agrees that each item of property (whether investment property, financial asset, security, instrument, general intangible or cash) credited to a Collateral Account to the extent that it constitutes a securities account shall be treated as a “financial asset” within the meaning of Section 8-102(a)(9) of the UCC.

  • Financial Accounts Exhibit E, as may be updated by the Borrower in a written notice provided to Agent after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor.

  • Investment Property (a) If such Grantor shall become entitled to receive or shall receive any stock or other ownership certificate (including any certificate representing a stock dividend or a distribution in connection with any reclassification, increase or reduction of capital or any certificate issued in connection with any reorganization), option or rights in respect of Stock and Stock Equivalents in any issuer thereof, whether in addition to, in substitution of, as a conversion of, or in exchange for, any shares of or other ownership interests in the Pledged Securities, or otherwise in respect thereof, such Grantor shall accept the same as the agent of the Secured Parties, hold the same in trust for the Secured Parties and promptly deliver the same to the Administrative Agent in the exact form received (other than Excluded Stock), duly endorsed by such Grantor to the Administrative Agent, if required, together with an undated stock power or similar instrument of transfer covering such certificate duly executed in blank by such Grantor and with, if the Administrative Agent so requests, signature guaranteed, to be held by the Administrative Agent, subject to the terms hereof, as additional collateral security for the Obligations. Any sums paid upon or in respect of the Pledged Securities upon the liquidation or dissolution of any issuer thereof shall be paid over to the Administrative Agent to be held by it hereunder as additional collateral security for the Obligations if an Event of Default then exists, and in case any distribution of capital shall be made on or in respect of the Pledged Securities or any property shall be distributed upon or with respect to the Pledged Securities pursuant to the recapitalization or reclassification of the capital of any issuer thereof or pursuant to the reorganization thereof, the property so distributed shall, if an Event of Default then exists, and unless otherwise subject to a perfected security interest in favor of the Administrative Agent, be delivered to the Administrative Agent to be held by it hereunder as additional collateral security for the Obligations. If any sums of money or property so paid or distributed in respect of the Pledged Securities shall be received by such Grantor in violation of the immediately preceding sentence, such Grantor shall, until such money or property is paid or delivered to the Administrative Agent, hold such money or property in trust for the Secured Parties, segregated from other funds of such Grantor, as additional collateral security for the Obligations.

  • Collection of Accounts, General Intangibles and Negotiable Collateral At any time upon the occurrence and during the continuance of an Event of Default, Agent or Agent’s designee may (a) notify Account Debtors of any Grantor that the Accounts, General Intangibles, Chattel Paper or Negotiable Collateral of such Grantor have been assigned to Agent, for the benefit of the Lender Group and the Bank Product Providers, or that Agent has a security interest therein, and (b) collect the Accounts, General Intangibles and Negotiable Collateral of any Grantor directly, and any collection costs and expenses shall constitute part of such Grantor’s Secured Obligations under the Loan Documents.

  • Eligible Investments The following are Eligible Investments:

  • Deposit Account Transactions (a) The Bank or its Subcustodians will make payments from the Deposit Account upon receipt of Instructions which include all information required by the Bank.

  • The Investment Account; Eligible Investments (a) Not later than the Withdrawal Date, the Master Servicer shall withdraw or direct the withdrawal of funds in the Custodial Accounts for P&I, for deposit in the Investment Account, in an amount representing:

  • FINANCIAL ASPECTS The cost of this TRIAL has been initially budgeted at   EUROS, not including VAT, (€ ) (hereinafter, the TRIAL Budget), in accordance with the provisions of the Financial Memorandum for the TRIALS (Schedule I), which specifies all their financial aspects. This amount does not, in any case whatsoever, include an obligation or inducement for the HOSPITAL, the FOUNDATION, and/or the LEAD INVESTIGATOR to recommend, prescribe, buy, use or arrange the use of any of the SPONSOR’s products. To request an invoice, contact: xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx In addition, upon signature of this contract, the SPONSOR/CRO (choose as appropriate) will pay the amount of 4,000/3,000 Euros, in a one-time, non-refundable payment, as administrative and contractual management costs. This payment will include expenses for CEIm evaluation, relevant amendments, contract management administration and addendum to the contract. This payment will include expenses for contract management administrative procedures and addendum to the contract. If the fiscal details of this invoice are different from those detailed for visitor invoices in clause 5.4., please indicate them below: Invoices will be issued to: Name: CIF/VAT number / Tax ID Number: Domicile / Registered Address:  Invoices will be sent for processing to the following e-mail:   The amount to be paid by the SPONSOR/CRO (choose as appropiate) during performance of the TRIALS will be calculated by applying Schedule I and must be paid to the FOUNDATION in the payments set out below: The TRIALS budget will be paid, at least, every six months in accordance with the details in the amounts table by visit and subject signed up included in Schedule I, until the total amount of the Budget has been paid. For that purpose, SPONSOR/CRO (choose as appropiate) and the LEAD INVESTIGATOR will report to the FOUNDATION every six months. These payments are considered to be payments on account, pending payment of the definitive total for the TRIALS. The definitive total to be paid by the SPONSOR/CRO (choose as appropiate) for performing the TRIALS will be calculated based on the work effectively carried out to perform the TRIALS (hereinafter, the Definitive Total). The Definitive Total will be calculated as follows: Within a maximum of three (3) months after termination of the TRIALS at the HOSPITAL, the SPONSOR/CRO (choose as appropiate) SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will notify the FOUNDATION in writing of the total number of: (1) subjects signed up and assessed, (2) visits effectively paid, (3) incidents occurring, and (4) any hospital test, analysis, exploration, appointment or stay of an extraordinary nature which may have occurred, whether or not they are reflected in the Financial Memorandum (Schedule I). As soon as possible after the information referred to in the previous paragraph has been notified, the FOUNDATION will calculate, issue and notify the SPONSOR/CRO (choose as appropiate), in a final invoice for the trials, the amount of the definitive total and, if necessary, claim the amounts pending payment, which must be paid within one (1) month, without the need for a subsequent request. Once the final payment is made, it will be understood that the SPONSOR’s financial obligations have concluded. All payments must be made on submission of the invoice, to which VAT will be added in accordance with the applicable law on the date it is issued on, in the name of the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details) Name: CIF/VAT number / Tax ID Number: Domicile / Registered Address:  Invoices will be sent for processing to the following e-mail:   The SPONSOR/CRO must communicate by email to FIBHU12O the total amount that must be invoiced for the visits that have been made, detailing the breakdown of each of these visits and procedures detailed in the Economic Report (ANNEX_I). For this, must send an e-mail to xxxxxxxxxxx.xxxx@xxxxx.xxxxxx.xxx Payments to the FOUNDATION will be made by bank transfer, with charges payable by the sender, to: Holder/Beneficiary: Fundación para la Investigación Biomédica del Hospital Universitario 12 de octubre. Bank: Caixabank, S.A. Address: Xxxxx xx xx Xxxxxxxxxx, 00 0x 00000-Xxxxxx Account Nº/IBAN: XX00 0000 0000 0000 0000 0000 SWIFT CODE: CAIXE SBBxxx VAT number /Tax ID CODE: X-00000000 Payments made by the SPONSOR/CRO (choose as appropiate) to the FOUNDATION will be full settlements for the former, with the FOUNDATION being responsible for payment the amounts that, as appropriate, are payable to the TRIALS researchers. The PARTIES agree that, if the HOSPITAL lacks the necessary equipment for adequate performance of the TRIALS, the SPONSOR will provide the HOSPITAL with it, free-of-charge and assigning its use, either directly or via a third party. Furthermore, the SPONSOR will pay the cost, and arrange the supply, installation, maintenance, calibration and removal of the equipment, and training personnel in operating it, if necessary. The HOSPITAL, the FOUNDATION and the LEAD INVESTIGATOR will, in no case, be liable for its maintenance or its eventual loss. The equipment will consist of the following components:   The Equipment will remain the property of the SPONSOR, or a third party, and will carry the relevant identification to show this. The Equipment may only be used to perform the TRIAL and, when it has ended, will be returned to the SPONSOR, or a third party, at no cost to the HOSPITAL or the FOUNDATION. When the LEAD INVESTIGATOR receives a request for return, they will make the Equipment available to the SPONSOR, or the third party appointed by it to collect it. On termination of the TRIALS, the SPONSOR may assign the Equipment to the HOSPITAL free-of-charge, for which purpose such documents as are necessary will be formalised. In the event that additional needs for equipment are detected during performance of the TRIALS, subsequent to the signature of this contract, the PARTIES must sign an addendum including the equipment made available, respecting the terms and conditions set out in the previous paragraphs.

  • Securities Account All Permitted Investments have been and will be credited to a Securities Account. The securities intermediary for each Securities Account has agreed to treat all assets credited to the Securities Accounts as “financial assets” within the meaning of the applicable UCC.

Time is Money Join Law Insider Premium to draft better contracts faster.